MyoKardia, Inc. is pioneering a precision medicine approach to treating genetic heart disease.

By combining leading-edge cardiovascular genetics with recent advances in heart muscle biochemistry, MyoKardia seeks to revolutionize the treatment of cardiomyopathies and make a meaningful difference in the lives of the millions of people suffering from cardiovascular diseases.

Learn More

News & Events

04.30.15
MyoKardia, Inc. Completes $46 Million Series B Financing
Link

03.03.15
MyoKardia Announces Initiation of Phase 1 Clinical Study of MYK-461 for Hypertrophic Cardiomyopathy
Link